

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 18311

**Title:** Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease

**Reviewer's code:** 02941507

**Reviewer's country:** Greece

**Science editor:** Jing Yu

**Date sent for review:** 2015-04-18 13:52

**Date reviewed:** 2015-04-29 01:09

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

## COMMENTS TO AUTHORS

A very well written review Minor remarks 1. Page 8 line 4 "addressing" 2. Page 9 line 22 "facilitate" 3. In the conclusion part please provide the reader with a message regarding the mechanism(s) facilitating the interaction of nanoparticles and the cell membrane as well as clear message concerning the intracellular uptake of the drug and the vehicle. 4. Finally it might be interesting for the readers to give in the text some information concerning the oral nano-delivery systems for colon targeted drug delivery in IBD (Hua et al Nonomedicine 2015 Mar 14. Pii: S1549-9634(15)00068-4)

## ESPS PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastroenterology

**ESPS manuscript NO:** 18311

**Title:** Nanomedicine and drug delivery strategies for treatment of inflammatory bowel disease

**Reviewer's code:** 00189171

**Reviewer's country:** Hungary

**Science editor:** Jing Yu

**Date sent for review:** 2015-04-18 13:52

**Date reviewed:** 2015-05-06 00:32

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> [ Y ] Accept
<input checked="" type="checkbox"/> [ Y ] Grade B: Very good	<input checked="" type="checkbox"/> [ Y ] Grade B: Minor language polishing	<input type="checkbox"/> [ ] The same title	<input type="checkbox"/> [ ] High priority for publication
<input type="checkbox"/> [ ] Grade C: Good	<input type="checkbox"/> [ ] Grade C: A great deal of language polishing	<input type="checkbox"/> [ ] Duplicate publication	<input type="checkbox"/> [ ] Rejection
<input type="checkbox"/> [ ] Grade D: Fair	<input type="checkbox"/> [ ] Grade D: Rejected	<input checked="" type="checkbox"/> [ Y ] No	<input type="checkbox"/> [ ] Minor revision
<input type="checkbox"/> [ ] Grade E: Poor		BPG Search:	<input type="checkbox"/> [ ] Major revision
		<input type="checkbox"/> [ ] The same title	
		<input type="checkbox"/> [ ] Duplicate publication	
		<input type="checkbox"/> [ ] Plagiarism	
		<input checked="" type="checkbox"/> [ Y ] No	

## COMMENTS TO AUTHORS

Takedatsu et al. provided a very useful overview regarding the promising results of novel therapeutic option in IBD. AS nanoparticles has some advantageous properties compared to conventional medications, this kind of overview may help the clinicians to judge whether these molecules could be a useful part of our arsenal in the daily practice. I have some remarks regarding this manuscript. Major concerns: I feel that the authors are very committed to nanoparticles. Their benefits are overestimated in my opinion. There should be more critical part in the discussion section (which is very short compared to length of the whole manuscript). E.g.: Rectally administered nanoparticles (and their delivery systems) won't raise the attention of a clinician, as locally administered 5-ASAs are effective, tolerable and cheap medications. More criticism should be used in the IL-10 section, also. In the same time, adverse events (infection, tumour-issue, antibodies, allergy, etc.) with the conventionally used biologics are emphasized. Indicating the exact odds ratios regarding these side effects would make the manuscript more balanced. A table reviewing the possible delivery systems and their mechanisms of action would enhance the value of the manuscript.



## BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

It is not easy to understand the text fulfilled with lots of abbreviations. Minor remarks: Significance of Smad7 ASO treatment is emphasized in the abstract. As the manuscript overviews lots of modalities, it is not favoured to stress one in the abstract section, in my opinion. Authors should check the formal requirements of WJG (reference numbering are correct?) Certolizumab and golimumab are also the members of anti-TNF families, these should be mentioned in the last paragraph of page 3. In summary, this paper give a very useful review regarding NPs in IBD treatment, however some more criticism would make it more reasonable to a clinician. A table representing the most important members of this family (and their delivery systems) would enhance the value of the manuscript.